Using the minimal effective dose of GLP-1 medications may be the key to preserving muscle during weight loss. This episode explains how to implement it alongside nutrition and training.

A clinical deep dive into the muscle loss problem on GLP-1 medications. Semaglutide, tirzepatide, and the investigational triple agonist retatrutide all produce remarkable weight loss — but clinical trial data shows that a significant fraction of that loss is lean body mass, not fat. This episode covers the mechanism behind GLP-1-induced muscle wasting, the body composition data from STEP 1 and SURMOUNT trials, who carries the highest risk, and where the next generation of obesity pharmacology — bimagrumab combinations, pemvidutide, and retatrutide's glucagon receptor pathway — is trying to solve the problem. For clinicians, patients, and anyone paying attention to where obesity medicine is actually going.

This podcast is for informational purposes only and is not medical advice.

Breaking news episode. On April 15, 2026, the FDA formally initiated the reclassification process for BPC-157, TB-500, and other peptides restricted since 2023 — publishing a Federal Register notice and scheduling a July 2026 Pharmacy Compounding Advisory Committee meeting. This episode breaks down the full regulatory timeline, what the Category 1 vs Category 2 framework means, what today's action specifically does, and what patients and clinicians should know right now. Clinical, evidence-grounded, no hype.

A clinical breakdown of grey market peptide safety, including contamination risks, testing standards, and how peptide quality impacts biological effects.

GHK-Cu Explained: The Science Behind the Copper Peptide for Skin, Hair, and Healing

A clinical deep dive into BPC-157 covering mechanism, recovery science, dosing patterns, TB-500 synergy, and why it is banned in professional sports.

Are peptides dangerous—or just misunderstood?

In this episode of Peptides Explained, we break down the real science behind peptide safety, how these compounds work in the body, and where risk actually exists.

You’ll learn:

• what peptides are and how they function biologically
• the difference between FDA-approved, compounded, and research peptides
• what changed with peptide regulation and access
• how off-label prescribing fits into modern medicine
• what recent conversations are getting right—and wrong

This episode focuses on clarity—not hype—so you can understand how peptides fit into real clinical practice.

MOTS-C is one of the most unique peptides being studied today — not because of what it does, but because of where it comes from.

Unlike most peptides, MOTS-C is encoded inside your mitochondria, the part of the cell responsible for energy production. That makes it part of a growing category of mitochondrial signaling peptides that may play a role in metabolism, aging, and cellular energy regulation.

In this episode of Peptides Explained, we break down:

• What MOTS-C is and how it’s produced
• How it activates AMPK, the body’s metabolic “master switch”
• Why it’s being studied as a potential exercise mimetic
• Its effects on insulin sensitivity and glucose metabolism
• What the animal research shows vs. the current state of human data
• Where it may fit in the broader peptide landscape
• Risks, limitations, and why it remains experimental

This episode focuses on the biology and clinical context behind MOTS-C — not the hype.

Disclaimer: This podcast is for informational purposes only and is not medical advice. MOTS-C is not FDA-approved and is currently considered an investigational peptide. Always consult a licensed healthcare professional before considering any therapy.

Peptide science is evolving — and understanding the mechanism is the first step.

Growth hormone peptides are some of the most talked-about compounds in longevity medicine, metabolic health, and hormone optimization. But how do they actually work inside the body?

In this episode of Peptides Explained, we break down the science behind four growth hormone secretagogues: Sermorelin, Tesamorelin, CJC-1295, and Ipamorelin.

Instead of injecting growth hormone directly, these peptides stimulate the pituitary gland to release the body’s own growth hormone through different biological pathways.

We explore the physiology of the growth hormone axis, the role of GHRH, IGF-1, and ghrelin signaling, and how these peptides may influence metabolism, recovery, and sleep.

You’ll also learn the differences between these compounds, why CJC-1295 and Ipamorelin are often stacked, and what the clinical research actually shows.

Topics covered in this episode include:

• How growth hormone is regulated in the body
• The biological role of ghrelin and GH pulses during sleep
• The difference between Sermorelin, Tesamorelin, CJC-1295, and Ipamorelin
• What DAC (Drug Affinity Complex) means in CJC-1295
• Potential effects on IGF-1, metabolism, and recovery
• Possible side effects, including effects on prolactin and glucose metabolism
• What the clinical evidence actually supports

As always, this podcast focuses on biological mechanisms and scientific evidence so you can understand how peptide therapies interact with human physiology.

Disclaimer:
This episode is for informational purposes only and does not constitute medical advice. Always consult a licensed healthcare professional before considering any therapy.

If you'd like, I can also give you a very effective pinned comment for the YouTube video. That small detail often increases engagement and pushes the algorithm to recommend the episode more.

In Episode 3 of Peptides Explained, we take a closer look at two of the most talked-about peptides in injury recovery circles: BPC-157 and TB-500.

These compounds are often combined in what’s popularly called the “Wolverine Stack,” a nickname that reflects claims of accelerated healing and recovery. But what are these peptides actually doing in the body, and what does the science really say?

In this episode, we break down the biology behind both compounds, how they interact with tissue repair pathways, and why they’ve become so popular in athletic and performance communities.

We discuss:

• What BPC-157 is and how it may influence angiogenesis, tendon repair, and tissue healing
• What TB-500 (a fragment related to thymosin beta-4) does in terms of cell migration and tissue remodeling
• The biological rationale behind combining the two peptides
• What the available animal research suggests — and where human clinical data is still lacking
• Why these peptides remain in a regulatory gray area
• The difference between experimental compounds and FDA-approved peptide therapeutics

The goal of Peptides Explained is clarity, not hype. In each episode we examine the mechanisms, the available data, and the real limitations of what we know today.

Disclaimer:
This podcast is for informational purposes only and does not constitute medical advice. Peptides discussed may have different regulatory statuses and should only be used under the guidance of licensed healthcare professionals.

If you’re interested in the science behind peptides, injury recovery, metabolism, and emerging therapeutic pathways, this episode will give you a clear, evidence-based overview of one of the most talked-about peptide combinations today.